MIR.V - MedMira Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.6100
+0.1300 (+27.08%)
As of 2:39PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.4800
Open0.4850
Bid0.6100 x 0
Ask0.6200 x 0
Day's Range0.4850 - 0.6100
52 Week Range0.0100 - 0.8900
Volume3,047,238
Avg. Volume4,754,108
Market Cap401.602M
Beta (5Y Monthly)16.15
PE Ratio (TTM)N/A
EPS (TTM)-0.0030
Earnings DateMar. 31, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    MedMira Reports Third Quarter Results FY2020

    HALIFAX, Nova Scotia, June 29, 2020 -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2020.  Important Notice The.

  • CNW Group

    IIROC Trading Resumption - MIR

    VANCOUVER , May 27, 2020 /CNW/ - Trading resumes in: Company: MedMira Inc. TSX-Venture Symbol: MIR (All Issues) Resumption (ET): 13:30 IIROC can make a decision to impose a temporary suspension (halt) ...

  • GlobeNewswire

    MedMira Announces Exclusive Distribution Partnership with Webb Diagnostic Technologies and Initial Order for REVEALCOVID-19™ Total Antibody Test in the U.S.

    MedMira Inc. (MedMira) (MIR.V) announces that company has entered into an Exclusive Distribution Agreement with Webb Diagnostic Technologies, Inc., (WebbDX) for the distribution of MedMira’s REVEALCOVID-19™ Total Antibody Test. Webb Diagnostic Technologies has placed the first order with the purchase value of approximately CDN$3.5 million. The Company has received the down payment to initiate the production process.

  • CNW Group

    IIROC Trading Halt - MIR

    VANCOUVER , May 27, 2020 /CNW/ - The following issues have been halted by IIROC: Company: MedMira Inc TSX-Venture Symbol: MIR (all issues) Reason: At the Request of the Company Pending News Halt Time (ET): 11:47 ...

  • GlobeNewswire

    MedMira Announces Progress Update of its REVEALCOVID-19™ Total Antibody Test Including CE Mark

    Today, MedMira Inc. (MedMira) (MIR.V) announced that it has completed the registration process and affixed the CE mark (Conformité Européene) to its rapid REVEALCOVID-19™ Total Antibody Test. MedMira declares conformity to all essential requirements outlined in the In Vitro Diagnostic Medical Devices Directive 98/79/EC. The Certificate of Registration has been obtained from the European Authorized Representative and the product is now registered in the German DIMDI data base as per Directive 98/79/EC of the European Parliament and of the Council of the European Union relating to in vitro diagnostic medical devices.

  • GlobeNewswire

    MedMira Announces Notification Submission to US FDA Emergency Use Authorization

    MedMira Inc. (MedMira) (MIR.V), announced today that it had submitted the notification for the Emergency Use Authorization application offered by the U.S. Food and Drug Administration (FDA) for its newest member of its Reveal line of products for antibody testing. The FDA policy announced on March 16, 2020 permits MedMira to begin U.S. sales of REVEALCOVID-19TM total antibody test immediately while it awaits FDA clearance under Emergency Use Authorization (EUA).

  • GlobeNewswire

    MedMira Announces Update on Development of Point-of-Care Antibody Test

    MedMira Inc. (MedMira) (MIR.V), announced today that it has completed the development of the serological Point-of-Care (POC) testing solution with immediate result. Based on MedMira’s unique and patented Rapid Vertical Flow® (RVF) technology, the newly developed REVEALCOVID-19TM delivers immediate results without the need for any additional equipment such as a reader or a timer. The product is subject to obtaining regulatory approvals to sell in the selected markets.

  • GlobeNewswire

    MedMira Reports Second Quarter Results FY2020

    MedMira Inc. (MedMira) (MIR.V), reported today on its financial results for the quarter ended January 31, 2020. Revenue: The Company recorded revenues in Q2 FY2020 of $95,012 compared to $129,990 in Q2 FY2019. The decrease of these revenues was due a change in ordering patterns by the Company’s main customer.

  • Does MedMira Inc.'s (CVE:MIR) CEO Pay Matter?
    Simply Wall St.

    Does MedMira Inc.'s (CVE:MIR) CEO Pay Matter?

    In 2006 Hermes Chan was appointed CEO of MedMira Inc. (CVE:MIR). First, this article will compare CEO compensation...

  • GlobeNewswire

    MedMira Reports First Quarter Results FY2020

    MedMira Inc. (MedMira) (MIR.V), reported today on its financial results for the quarter ended October 31, 2019. Revenue: The Company recorded revenues in Q1 FY2020 of $89,132 compared to $155,065 in Q1 FY2019. As outlined in the next highlight this strategy has provided the Company a higher contribution margin and also had an indirect effect on lowering its expenses.

  • Did You Manage To Avoid MedMira's (CVE:MIR) Painful 70% Share Price Drop?
    Simply Wall St.

    Did You Manage To Avoid MedMira's (CVE:MIR) Painful 70% Share Price Drop?

    Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly...

  • GlobeNewswire

    MedMira Reports 2019 Fourth Quarter and Year End Financial Results

    MedMira Inc. (MedMira) (MIR.V), reported today on its financial results for the financial year ended July 31, 2019. Revenue: The Company recorded revenues in FY2019 of $527,445 compared to $574,860 in FY2018. The decrease in revenue was due to the Company’s strategy to focus on high profit margin markets.

  • Is MedMira Inc.'s (CVE:MIR) CEO Pay Justified?
    Simply Wall St.

    Is MedMira Inc.'s (CVE:MIR) CEO Pay Justified?

    Hermes Chan became the CEO of MedMira Inc. (CVE:MIR) in 2006. This analysis aims first to contrast CEO compensation...